Scientific advances in understanding cancer, coupled with innovative treatment breakthroughs, mean that cancer care has been transformed in recent years, and more people than ever will survive the disease.¹

At Pfizer, we are committed to the discovery and development of pioneering therapies that continue to improve the outlook for cancer patients. Over the past decade, we've taken bold new approaches to translate innovative scientific research into meaningful breakthrough medicines for people living with cancer. And we won't stop there.

We're striving to advance the frontiers of cancer biology to develop a new generation of cutting edge therapies, across multiple cancers and tumour types for which an unmet need exists. Each day, our scientists are working towards discovering new breakthroughs that could save lives.

Our pipeline includes biologics, small molecules, immunotherapies and biosimilars, and is centred on exploring a multitude of approaches across many tumour types.^{​​​​​​​}

We are focused on exploring genetic, phenotypic, and functional biomarkers to help guide clinical research strategies and ensure the right patients are treated with the right medicines. Our goal is to develop therapies with potentially transformational outcomes.

Specific area of interest include:^{​​​​​​​}

• new chemical entities (NCEs)
• monoclonal antibodies (mAbs)
• antibody drug conjugates
• oncogenic drivers / cell signalling
• anti-angiogenics
• cancer stem cell metabolism, and epigenetics
• bi-specifics
• vaccines